ReviewJournal of neuro-oncology2005
Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study.
Review in Journal of neuro-oncology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systemic therapy in the treatment of recurrent or refractory intracranial meningiomas: A systematic review and individual patient data meta-analysis.Neurosurgical review · 2026Pooled it
- Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.Journal of neuro-oncology · 2012Trial
- Diarylpentanoid, a curcumin analog, inhibits malignant meningioma growth in bothWorld journal of experimental medicine · 2025Article
- Review
- Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review.Surgical neurology international · 2018Review
- The Clinical Outcome of Hydroxyurea Chemotherapy after Incomplete Resection of Atypical Meningiomas.Brain tumor research and treatment · 2017Article
- Re-evaluation of cytostatic therapies for meningiomas in vitro.Journal of cancer research and clinical oncology · 2014Article
- A case of recurrent anaplastic meningioma of the skull base with radiologic response to hydroxyurea.Journal of neurological surgery reports · 2014Article
- Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.Neuro-oncology · 2014Review
- Role of external beam radiotherapy in the treatment of relapsing meningioma.Medical oncology (Northwood, London, England) · 2014Article
- Medical management of meningiomas.CNS oncology · 2013Review
- Is there effective systemic therapy for recurrent surgery- and radiation-refractory meningioma?CNS oncology · 2013Article
- Stereotactic radiosurgery for WHO II and III meningiomas: analysis of long-term clinical and radiographic outcomes.Journal of radiosurgery and SBRT · 2013Article
- Long-term follow-up result of hydroxyurea chemotherapy for recurrent meningiomas.Journal of Korean Neurosurgical Society · 2012Article
- Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.Journal of neuro-oncology · 2012Article
- Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma.Journal of neuro-oncology · 2012Article
- Management of intracranial meningiomas in Enugu, Nigeria.Surgical neurology international · 2012Article
- Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series.Journal of neuro-oncology · 2011Article
- Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization.Frontiers in oncology · 2011Article
- Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.Journal of neuro-oncology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTreatment of recurrent and progressive meningiomas remains a challenge in clinical neurooncology. This study was designed to evaluate the efficacy of the simultaneous application of 3d-conformal radiotherapy and chemotherapy with hydroxyurea (HU). PATIENTS AND
methodsTwenty-one patients with recurrent or progressive meningiomas (13 benign, 4 atypical and malignant, 4 with unproven histology) received treatment by fractionated 3d-conformal radiation (55.8-59.4 Gy) and concurrent HU, administered for a median time of three months with a daily dosage of 20 mg/kg. Response was evaluated using clinical and neuro-imaging data.
resultsDisease stabilization was achieved in 14/21 patients (pts). Three pts had significant improvement of tumor associated neurological symptoms with imaging criteria of minor response. Progression free survival rates 1 year and 2 years after the initiation of radio-chemotherapy were 84% and 77%, respectively. At the time of analysis a total of 6/21 pts presented with progressive disease with a median time to progression of 59 weeks. Documented radio- and chemotherapy associated toxicity was minimal; only one patient discontinued HU treatment due to gastrointestinal symptoms such as anorexia and weight loss.
conclusionResults obtained in this study indicate that treatment with HU and simultaneous radiotherapy is safe and effective with disease stabilization in the majority of patients. Randomized trials comparing radiosurgery versus radiochemotherapy versus fractionated radiotherapy are warranted.
Indexed as
Identifiers
16193387What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.